| 名稱 | EGFR L858R-T790M-C797S/BaF3 |
| 型號 | CBP73049 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | EGFR L858R-T790M-C797S/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 選擇性組蛋白去乙?；敢种苿┰谀[瘤免疫治療中的作用及前景
- ATCC細(xì)胞冷凍保存方法
- 肥胖與腫瘤治療新星靶點(diǎn)——GDF15-GFRAL
- 強(qiáng)強(qiáng)聯(lián)合！IBM與MIT開展腫瘤藥物抗藥性研究
- CYP2C19基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
- 上海生科院發(fā)現(xiàn)PKM2抑制細(xì)胞凋亡的新機(jī)制
- 上海細(xì)胞中心人員需了解的專業(yè)“術(shù)語”
- 圣誕節(jié)日，這株腫瘤細(xì)胞你的圣誕襪里，有嗎
- 潛力十足的T細(xì)胞療法，我們用得起嗎？
- 示蹤細(xì)胞在活體成像技術(shù)中的應(yīng)用
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73049EGFR L858R-T790M-C797S/BaF3
- 詳細(xì)內(nèi)容
| CBP73049 | |
| I. Introduction | |
Cell Line Name： | EGFR L858R-T790M-C797S/BaF3 |
Host Cell: | Ba/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
| II.Background | |
EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section). In ligand-activated cancers, Cetuximab appears to be more effective than tyrosine-kinase inhibitors. | |
| III. Representative Data | |
1. WB of EGFR-L858R/T790M/C797S expression | |
| |
Figure 1. WB of EGFR Expression Lane 1: Negative control Lane 2: EGFR-WT Lane 3: EGFR-L858R/T790M Lane 4: EGFR-L858R/T790M/C797S | |
2. Sanger sequencing | |
| |
Figure 2. Sanger Sequencing of EGFR-L858R/T790M/C797S | |
3. Anti-proliferation assay | |
| |
Figure 3. Anti-proliferation assay of three reference compounds on the EGFR L858R-T790M-C797S/BaF3 Stable Cell Line | |
